Tuesday May 12, 2026
Coming to you a day late this week… again. This time, we held the digest so we could capture the opening signals from MedTech World North America in West Palm Beach, which kicked off yesterday and runs through Wednesday.
The week told two stories at once. On one side, AI-driven consolidation accelerated as Roche put a real number on the digital pathology market and Google pushed deeper into ambient consumer health. On the other, incumbents kept restructuring under pressure: Siemens Healthineers trimmed guidance and floated a Diagnostics spinoff, Medtronic announced it will close a 28-year-old California site, and the FDA flagged a new supply shortage that will hit OR-dependent product lines through year-end. The throughline: the platforms that can absorb AI and reorganize fast keep widening their lead, and everyone else is in catch-up mode.
8 things to watch this week:
1. 🤝 Roche to acquire PathAI for up to $1.05B
Roche signed a definitive deal Thursday to acquire Boston-based digital pathology firm PathAI for $750M upfront plus up to $300M in milestones, bringing in-house an AI partner it has worked with since 2021. The deal signals that diagnostics consolidation around AI is moving from collaboration to ownership — and validates premium valuations for AI-enabled diagnostic platforms with established commercial traction.
MedTech Dive
2. 📉 Siemens Healthineers cuts 2026 outlook, opens door to Diagnostics carve-out
Citing a 6.5% revenue decline in Chinese diagnostics and pronounced inflation, Siemens trimmed FY2026 revenue growth guidance to 4.5–5% (from 5–6%) and announced a leadership reshuffle on May 7. CEO Bernd Montag said the company is “initiating the next steps to create options for Diagnostics” — strategy-speak markets are reading as a potential carve-out, with major implications for the global IVD landscape.
MassDevice
3. ⌚ Google launches $99 screenless Fitbit Air; rebrands app to Google Health
Google unveiled the Fitbit Air on May 7 — a 12-gram screenless tracker built around Gemini AI’s Health Coach with AFib detection, SpO2, HRV, and skin temperature tracking, all without a required subscription. The Fitbit app becomes “Google Health” on May 19, signaling Big Tech’s continued push toward a regulated-adjacent consumer health stack and intensifying pressure on Whoop, Oura, and traditional wearables alike.
TechCrunch
4. 🎯 Most medical device companies don’t fail on technology. They fail on sequencing.
The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.
The CLIF Analysis from RŌG Health is a fast, structured external diagnostic designed to surface those gaps before they become costly. One week. Built for medical device and medtech teams.
Sponsored
5. 💉 Tandem to file tubeless Mobi insulin pump 510(k) this quarter
On its May 8 earnings call, Tandem said it will file a 510(k) for a tubeless version of its Mobi pump this quarter, with clearance expected in 2H 2026 and a phased launch to follow. The move targets the ~20% growth tubeless segment currently dominated by Insulet — and gives clinicians a single platform that can switch between tubed and tubeless wear, a first in the category.
MedTech Dive
6. 🏭 Medtronic to close Santa Rosa operations, relocate 370 jobs by 2028
Medtronic informed Santa Rosa employees on May 7 that it will fully exit the California site over the next two years, shifting production primarily to Santa Ana, Minneapolis-area facilities, and Galway, Ireland. The wind-down ends a 28-year footprint that began with the $3.7B Arterial Vascular Engineering acquisition — and continues the consolidation playbook large medtechs are running to offset tariffs and protect margin.
Press Democrat
7. ⚠️ FDA warns of neurosurgical sponge and patty shortages through 2026
The FDA added neurosurgical patties, sponges, and strips to its device shortage list on May 6 following Medline’s recall of products with elevated endotoxin levels. The disruption affects fluid-absorbing devices used across cranial and spine procedures, and the agency expects supply pressure to persist through year-end — a procedure-volume risk for OR-dependent product lines.
MedTech Dive
8. 🧠 FDA clears first at-home brain stimulation device for major depression
Flow Neuroscience’s FL-100 transcranial direct-current stimulation system received FDA authorization, becoming the first prescription at-home tDCS device cleared in the U.S. for moderate-to-severe MDD in adults — as monotherapy or adjunct. Launch is targeted for Q2 via iOS and Android, opening a new neuromodulation category and pressuring both pharmaceutical antidepressants and clinic-bound neuromodulation incumbents.
Patient Care Online
BONUS STORY
🔒 Cybersecurity now the top driver of FDA premarket rejections
Industry experts headlining MedTech World North America (May 11–13, West Palm Beach) say premarket rejection rates have surged since the FDA finalized its updated cybersecurity guidance in February. The signal for connected-device makers: SBOMs, threat modeling, and post-market vulnerability management aren’t a final-checklist item — they’re a gating design input, and capital is sitting on the sidelines waiting for clarity.
Note: Check out the talk by MedTech World title sponsor and speaker Cristian Espinosa (founder and CEO at Blue Goat Cyber) on the topic this week!
Weekly Voice / MedTech World
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.